Merck (MRK) Cash from Operations (2009 - 2026)
Merck (MRK) reported Cash from Operations of 3918000000.0 for Q1 2026, up 56.72% year-over-year from 2500000000.0 in Q1 2025, and up 37.14% quarter-over-quarter from 2857000000.0 in Q4 2025.
Merck (MRK) Cash from Operations (2009 - 2026) Analysis & Trends
Merck (MRK) has 18 years of Cash from Operations data on file, last reported at 3918000000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 3918000000.0, up 56.72% year-over-year; the trailing twelve-month figure through Mar 2026 was 17890000000.0 (down 14.31% YoY), and the FY2025 annual result was 16472000000.0, down 23.27% from the prior year.
- Cash from Operations improved to 3918000000.0 in Q1 2026 per MRK's latest filing, from 2857000000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 9291000000.0 in Q3 2024 and troughed at 246000000.0 in Q4 2023.
- A 5-year average of 4350529411.76 and a median of 3918000000.0 in 2026 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations slumped 94.45% in 2023, then surged 1302.44% in 2024.
- A 5-year view of Cash from Operations shows it stood at 4430000000.0 in 2022, then tumbled by 94.45% to 246000000.0 in 2023, then surged by 1302.44% to 3450000000.0 in 2024, then retreated by 17.19% to 2857000000.0 in 2025, then soared by 37.14% to 3918000000.0 in 2026.
- Business Quant data shows MRK's Cash from Operations at 3918000000.0 in Q1 2026, 2857000000.0 in Q4 2025, and 7822000000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 1.82 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 5.33 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.51 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.83 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.92 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 2.19 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.54 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.62 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.10 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.92 Bn |
| Mar 31, 2026 | 3.92 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Dec 31, 2025 | 2.86 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Sep 30, 2025 | 7.82 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Jun 30, 2025 | 3.29 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Mar 31, 2025 | 2.50 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Dec 31, 2024 | 3.45 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Sep 30, 2024 | 9.29 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Jun 30, 2024 | 5.64 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Mar 31, 2024 | 3.09 Bn |
| Dec 31, 2023 | 246.00 Mn |
| Dec 31, 2023 | 246.00 Mn |